There's a deadly problem with one of the nation's major medical markets - vaccines.
The technology we use today to prevent diseases like the flu, chicken pox, and polio is hopelessly outdated.
It still relies on the delivery of a portion of the actual virus to the patient to develop immunity. Some of these agents are still grown in chicken eggs, just like they were back in the 1930s. And the vaccines themselves or their additives can still make people sick.
But what if you could develop a whole new class of vaccines that were actually safe using a synthetic DNA? Better yet, what if you could vaccinate yourself against HIV, cervical cancer, leukemia, and hepatitis?
The payoff would be tremendous...
Stocks to Buy Now
The Great Rotation Makes Stocks a Generational Buy
If you're not gearing up to get fully invested in 2013, you have no one to blame but yourself.
What's likely to happen - and soon - is being called the "Great Rotation" - an investment shift out of bonds and into equities. When this happens, smart investors are going to reap generational rewards. And it may have already started...
Last week $22.2 billion flowed into mutual funds and ETFs. That's the second-largest weekly flow on record. Of that total, $8.9 billion flowed into equity mutual funds, which is the most since March of 2000 and the fourth-largest weekly inflow ever.
This is what you've been waiting for. This is your time.
Here's how to get invested now and why.
Stocks to Buy: The Biggest Winner in the Apple-Samsung Divorce
There will be winners for investors as a result of the slow-motion split between Apple Inc. (Nasdaq: AAPL) and Samsung Electronics (SSNLF), but the stocks to buy are neither of the warring parties.
Instead, as the tech giants unwind a relationship in which Samsung supplied Apple with billions of dollars' worth of components for its popular iPhones and iPads, the real winners are the suppliers rushing to fill the void.
The once-cozy relationship began to sour a couple of years ago when Samsung began to introduce smartphones and tablets that Apple felt too strongly resembled its own.
Shortly afterward, Apple began filing patent lawsuits. Samsung countersued. The fight grew into a global war, with 50 separate patent suits in 10 countries spread over four continents.
The relationship grew frostier in 2011 as Samsung became the dominant vendor of smartphones based on Google Inc.'s (Nasdaq: GOOG) Android operating system and started taking market share from the iPhone.
In 2012, Apple started shifting more and more component purchases to other suppliers, a process that has accelerated in recent months.
Samsung's invoices to Apple have included memory chips, batteries and display screens in addition to the manufacture of Apple-designed processor chips found in the iPhone and iPad.
Samsung, in fact, provided 26% of the component costs of the iPhone 4, so there's plenty of new money suddenly available at the Apple trough.
Let's take a look at some stocks to buy as a result of the Apple-Samsung divorce.
To continue reading, please click here...
Solar Stocks to Buy: Three Companies Poised for Rebound
The majority of investors, when considering stocks to buy, have given up on solar companies.That's mostly due to a two-year beatdown of the sector and plenty of bad publicity from the demise of federally subsidized Solyndra.
But while the sector continues to suffer - more solar companies will likely go under in 2013 - a choice few are positioned to benefit from a rebound that will start this year.
One sure sign of better days ahead is that the sector has recently attracted interest from one of the world's most respected investors, Warren Buffett.
Just within the past month MidAmerican Energy Holdings Co., a subsidiary of Buffett's Berkshire Hathaway Inc. (NYSE: BRK.A, BRK.B), announced a deal to pay SunPower Corp. (Nasdaq: SPWR) between $2 billion and $2.5 billion for two California solar projects.
That followed MidAmerican's purchase of a 49% stake in an Arizona solar plant jointly owned by NRG Energy Inc. (NYSE: NRG) and First Solar Inc. (Nasdaq: FSLR), as well as the $2 billion purchase of a planned solar farm in San Luis Obispo, CA, also from First Solar.
Here's why Buffett has taken an interest.
To continue reading, please click here...
Here's Your Key to a Winning Financial Plan in 2013
If you're like most of the rest of us, you've probably made your fair share of New Year's resolutions by now.
If that's the case, here's one more "resolution" to add: Review my investment plan for 2013 and beyond.
As regular readers of my work know, I have a real love for old investing adages and aphorisms. And there's one that really applies to today's story.
Back during World War II, British Prime Minister Winston Churchill told listeners that "he who fails to plan is planning to fail."
And was he ever right.
So many investors fail precisely because they "wing it" and don't have a plan of any kind.
It's not the plan itself that's really so important; it's the insights that you gain from creating the plan that are the real benefit. You reassess - and remind yourself of - such things as:
Here are some tips that will help you map out your financial plan for 2013:
If that's the case, here's one more "resolution" to add: Review my investment plan for 2013 and beyond.
As regular readers of my work know, I have a real love for old investing adages and aphorisms. And there's one that really applies to today's story.
Back during World War II, British Prime Minister Winston Churchill told listeners that "he who fails to plan is planning to fail."
And was he ever right.
So many investors fail precisely because they "wing it" and don't have a plan of any kind.
It's not the plan itself that's really so important; it's the insights that you gain from creating the plan that are the real benefit. You reassess - and remind yourself of - such things as:
- Your risk tolerances.
- Your current financial situation, as well as where you eventually want to be.
- Any ancillary issues (like saving for your son's college education, or making sure you can handle taking care of an elderly parent).
- Any problem investments you might be holding, or any "holes" in your allocations that need to be filled.
- And the steps you need to be taking to actually meet all of these goals.
Here are some tips that will help you map out your financial plan for 2013:
To continue reading, please click here...
Stocks to Buy in 2013: Don't Miss the New Developed Market Leaders
When looking for stocks to buy in 2013, many investors turn to the markets that outperformed the Standard & Poor's 500 Index in 2012.
For example, they might like Germany. The MSCI iShares Germany Index Fund (NYSE: EWG) soared more than 32% in 2012.
That's far better than the 15% gain from the S&P 500. It's also much stronger than the 15% gain from the iShares MSCI EAFE Index Fund (NYSE: EFA), which tracks developed-market equities in Europe, Australia, Asia and the Far East.
But amid slowing growth and frothy equity valuations, German stocks appear unlikely to continue such performance in 2013.
That's why investors should check out these other developed market players ready to soar in 2013. They're all expected to deliver gains that could rival Germany's explosive 2012 profits.
For example, they might like Germany. The MSCI iShares Germany Index Fund (NYSE: EWG) soared more than 32% in 2012.
That's far better than the 15% gain from the S&P 500. It's also much stronger than the 15% gain from the iShares MSCI EAFE Index Fund (NYSE: EFA), which tracks developed-market equities in Europe, Australia, Asia and the Far East.
But amid slowing growth and frothy equity valuations, German stocks appear unlikely to continue such performance in 2013.
That's why investors should check out these other developed market players ready to soar in 2013. They're all expected to deliver gains that could rival Germany's explosive 2012 profits.
To continue reading, please click here...
Three Stocks to Buy in Next Year's Most Promising Sectors
Whatever 2013 brings for the markets, there will be plenty of quality stocks to buy - if you know where to look.
Overall, the markets are expected to have another positive year.
A survey of 10 top financial strategists by Barron's projects the Standard & Poor's 500 will close at 1,562 in 2013, a 10% gain from current levels. (By the way, last year's picks outpaced the broader index by 6%.)
That would follow modest gains in 2012 of 13.5% for the S&P 500 and 8% for the Dow Jones Industrial Average.
For next year, Wall Street's top guns predict certain sectors of the market - technology, industrials, and energy - will lead the charge higher. Companies in more defensive sectors like consumer staples, telecoms, and utilities, will be laggards.
So let's take a closer look at three stocks to buy from among these favored sectors that should be an excellent place for your money in 2013.
That's cheap versus historical levels.
Tech is also a bellwether for when companies start to invest capital.
"When we get an upturn in capital expenditures, it will show up in tech first," Barclays' Barry Knapp told Barron's.
One stock to buy that has a rock solid balance sheet and a mountain of cash is Cisco Systems Inc. (Nasdaq: CSCO).
Once the world's most valuable company with a market cap of $500 billion, Cisco's shares sank sharply when the tech bubble burst in 2000.
And the stock is still dirt cheap, trading around $20 a share, roughly 10 times next year's earnings. Plus, the company is sitting on more than $48 billion in cash, worth about $9 a share.
With a dominant market share of 60%, CSCO is the de facto choice in the switching market.
Overall, the markets are expected to have another positive year.
A survey of 10 top financial strategists by Barron's projects the Standard & Poor's 500 will close at 1,562 in 2013, a 10% gain from current levels. (By the way, last year's picks outpaced the broader index by 6%.)
That would follow modest gains in 2012 of 13.5% for the S&P 500 and 8% for the Dow Jones Industrial Average.
For next year, Wall Street's top guns predict certain sectors of the market - technology, industrials, and energy - will lead the charge higher. Companies in more defensive sectors like consumer staples, telecoms, and utilities, will be laggards.
So let's take a closer look at three stocks to buy from among these favored sectors that should be an excellent place for your money in 2013.
Stocks to Buy in 2013: Cheap Tech
Tech stocks are hugely profitable and as a group currently carry a forward P/E ratio of about 11.That's cheap versus historical levels.
Tech is also a bellwether for when companies start to invest capital.
"When we get an upturn in capital expenditures, it will show up in tech first," Barclays' Barry Knapp told Barron's.
One stock to buy that has a rock solid balance sheet and a mountain of cash is Cisco Systems Inc. (Nasdaq: CSCO).
Once the world's most valuable company with a market cap of $500 billion, Cisco's shares sank sharply when the tech bubble burst in 2000.
And the stock is still dirt cheap, trading around $20 a share, roughly 10 times next year's earnings. Plus, the company is sitting on more than $48 billion in cash, worth about $9 a share.
With a dominant market share of 60%, CSCO is the de facto choice in the switching market.
To continue reading, please click here...
Stocks to Buy Now: Bet on these Three Casino Stocks for 2013
Rather than being suckered by the glamour and neon lights at casinos, savvy investors looking for stocks to buy now are putting the odds on their side and betting on "the house."
That's because casino stocks are promising big returns for shareholders.
Plus, the gaming industry is still in the early stages of what should be a sustained recovery from the financial crisis that had lightened gamblers' wallets.
But identifying the best casino stocks to buy now involves more than a weekend jaunt to Vegas.
Due diligence on gaming stocks now requires a look at gambling's biggest hotspot - Macau, a former Portuguese colony that is now a special administrative region under Chinese rule.
That's because casino stocks are promising big returns for shareholders.
Plus, the gaming industry is still in the early stages of what should be a sustained recovery from the financial crisis that had lightened gamblers' wallets.
But identifying the best casino stocks to buy now involves more than a weekend jaunt to Vegas.
Due diligence on gaming stocks now requires a look at gambling's biggest hotspot - Macau, a former Portuguese colony that is now a special administrative region under Chinese rule.
To continue reading, please click here...
The Next Profit Breakthrough: Synthetic Biology
Drug, chemical, and biofuel firms are relying more than ever on artificial fragments of DNA to invent new products. It's called synthetic biology.
For example, teams all over the world are now in their labs looking to create novel biotech compounds or drugs by inserting synthetic DNA into cells, either living or artificial. They're also growing new microorganisms that yield biofuels to be used in lieu of oil.
Trouble is, the process is so complex that it can take days to synthesize these man-made genes, usually in small batches.
Not only is it time consuming, but it requires the use of costly robots and other advanced gear. Simply stated, if someone came along with a breakthrough that greatly speeded up the development of synthetic genes, it could affect several industries at once, not to mention its own value in the market.
Allow me to introduce you to Gen9 Inc. The company is blazing a trail in the development of scalable technologies for synthesizing genes.
Now, Gen9 is a small, new dynamic company. And its potential is huge.
It was formed last summer around a unique new device that greatly speeds up the process of creating synthetic DNA.
Even better, it cuts the cost of that process by leaps and bounds.
For example, teams all over the world are now in their labs looking to create novel biotech compounds or drugs by inserting synthetic DNA into cells, either living or artificial. They're also growing new microorganisms that yield biofuels to be used in lieu of oil.
Trouble is, the process is so complex that it can take days to synthesize these man-made genes, usually in small batches.
Not only is it time consuming, but it requires the use of costly robots and other advanced gear. Simply stated, if someone came along with a breakthrough that greatly speeded up the development of synthetic genes, it could affect several industries at once, not to mention its own value in the market.
Allow me to introduce you to Gen9 Inc. The company is blazing a trail in the development of scalable technologies for synthesizing genes.
Now, Gen9 is a small, new dynamic company. And its potential is huge.
It was formed last summer around a unique new device that greatly speeds up the process of creating synthetic DNA.
Even better, it cuts the cost of that process by leaps and bounds.
To continue reading, please click here...
How to Choose the Best Global Value Stocks to Buy
It's no surprise investors are having a hard time finding strong stocks to buy.
After all, nobody's getting too excited about the recent rally. Europe is about to implode, Japan's in a coma, China's suffering a slowdown and the United States faces the possible fiscal cliff.
That's why I was talking to fund manager George Fraise of SGA Global Growth (MUTF: SGAGX) the other day, to find out where the growth - and potential for profit - is in the global market.
Fraise said he's very bullish on global value stocks, and outlined his strategy for picking the right ones.
After all, nobody's getting too excited about the recent rally. Europe is about to implode, Japan's in a coma, China's suffering a slowdown and the United States faces the possible fiscal cliff.
That's why I was talking to fund manager George Fraise of SGA Global Growth (MUTF: SGAGX) the other day, to find out where the growth - and potential for profit - is in the global market.
Fraise said he's very bullish on global value stocks, and outlined his strategy for picking the right ones.
To continue reading, please click here...
Letting Biotech Companies "Patent Nature" Could Be a Huge Boon for Investors
The U.S. Supreme Court has just agreed to hear a landmark case that could have extreme money-making ramifications for biotech companies.
Next June, the nine justices are expected to settle - once and for all - whether companies can patent human genes in the United States.
The Patent and Trademark Office has been issuing patents on DNA for nearly 30 years, according to Bloomberg Businessweek.
Roughly 4,000 of the 22,000 human genes now have some form of patent.
But the American Civil Liberties Union has challenged the practice in Association for Molecular Pathology v. Myriad Genetics. Now that case will go to the highest court in the country.
At heart, the legal question sounds simple: Does Myriad Genetics Inc. (NasdaqGS:MYGN) have the right to patent two genes that signal whether a woman is at higher risk of getting cancer of the breasts or ovaries?
Myriad of course did not invent or create the breast cancer predisposition genes, referred to as BRCA genes.
But it did create something called the BRACAnalysis test that looks for mutations on these genes. Those mutations are associated with much greater risks of breast and ovarian cancer.
Usually firms cannot get that kind of market protection for something that is clearly a product of nature. But in this case, Myriad has developed a process of extracting a gene that makes the resulting molecule novel and chemically different from DNA that naturally occurs in our bodies.
And, after all, it took Myriad 17 years and $500 million to develop the test. Without barriers to entry, other firms could simply come in, take advantage of all that costly effort and sell a knockoff for less money.
Even if that weren't illegal, it's obviously unfair.
Let's dig into the case and why it matters to you...
Next June, the nine justices are expected to settle - once and for all - whether companies can patent human genes in the United States.
The Patent and Trademark Office has been issuing patents on DNA for nearly 30 years, according to Bloomberg Businessweek.
Roughly 4,000 of the 22,000 human genes now have some form of patent.
But the American Civil Liberties Union has challenged the practice in Association for Molecular Pathology v. Myriad Genetics. Now that case will go to the highest court in the country.
At heart, the legal question sounds simple: Does Myriad Genetics Inc. (NasdaqGS:MYGN) have the right to patent two genes that signal whether a woman is at higher risk of getting cancer of the breasts or ovaries?
Myriad of course did not invent or create the breast cancer predisposition genes, referred to as BRCA genes.
But it did create something called the BRACAnalysis test that looks for mutations on these genes. Those mutations are associated with much greater risks of breast and ovarian cancer.
Usually firms cannot get that kind of market protection for something that is clearly a product of nature. But in this case, Myriad has developed a process of extracting a gene that makes the resulting molecule novel and chemically different from DNA that naturally occurs in our bodies.
And, after all, it took Myriad 17 years and $500 million to develop the test. Without barriers to entry, other firms could simply come in, take advantage of all that costly effort and sell a knockoff for less money.
Even if that weren't illegal, it's obviously unfair.
Let's dig into the case and why it matters to you...
To continue reading, please click here...
Stocks to Buy Now: Don't Miss This Looming M&A Wave
As investors hunting for the best stocks to buy, we often get so caught up in the big names of the day that we miss a powerful opportunity right in our community.
I'm talking about community bank stocks, and they're about to offer you one of the biggest profit opportunities of the next few years.
In fact, patient long-term investors could see profits similar to those enjoyed in the 1990s as banks recovered and consolidated.
Between 2006 and the depths of the credit crisis, the NASDAQ Bank Index plunged by more than 60% and has not really recovered. Some of the poorly managed ones lost it all and were liquidated by the Federal Deposit Insurance Corp. (FDIC).
Those that are left should benefit from the eventual recovery of the real estate markets - but the truth is most of these banks won't be around that long.
That's because as the credit crisis unfolded legislators and regulators were quick to react - or overreact. They applied new rules and regulation not just to the large institutions that caused most of the problems, but also to the smaller community banks.
With literally hundreds of new banking regulations on the way, many smaller banks simply will not be able to comply and still operate profitably. It will also be difficult for smaller banks to access the capital markets to raise the money needed to grow.
The most logical course of action will be to sell out to a larger institution.
I'm talking about community bank stocks, and they're about to offer you one of the biggest profit opportunities of the next few years.
In fact, patient long-term investors could see profits similar to those enjoyed in the 1990s as banks recovered and consolidated.
Stocks to Buy: Why It's Time for Small Banks
Community banks usually have just a few branches and less than $1 billion in deposits. They have seen their stock prices fall dramatically over the past few years from the peaks reached in the 2006 boom days.Between 2006 and the depths of the credit crisis, the NASDAQ Bank Index plunged by more than 60% and has not really recovered. Some of the poorly managed ones lost it all and were liquidated by the Federal Deposit Insurance Corp. (FDIC).
Those that are left should benefit from the eventual recovery of the real estate markets - but the truth is most of these banks won't be around that long.
That's because as the credit crisis unfolded legislators and regulators were quick to react - or overreact. They applied new rules and regulation not just to the large institutions that caused most of the problems, but also to the smaller community banks.
With literally hundreds of new banking regulations on the way, many smaller banks simply will not be able to comply and still operate profitably. It will also be difficult for smaller banks to access the capital markets to raise the money needed to grow.
The most logical course of action will be to sell out to a larger institution.
To continue reading, please click here...
The Best Stocks to Buy According to Top Hedge Funds
Knowing the best stocks to buy, and when to buy them, can be a daunting task.
But looking at the moves of the largest hedge funds enables investors to gain insight into what the big boys are doing.
FactSet Research Systems Inc. (NYSE: FDS), a financial research firm that provides analysis of the markets' biggest players, recently released its quarterly report on the stock positions held by the 50 largest hedge funds.
While the top held stock, Apple Inc. (Nasdaq: AAPL), had its exposure in the overall funds reduced by 1.8 million shares, the list of most added stocks might surprise you.
Best Stocks to Buy: Where Hedge Funds are Investing
In the third quarter, overall the top 50 hedge funds increased their exposure to stocks by 3%.
Here's a rundown of the top 10 stocks that the top hedge funds were buying last quarter, listed in order by the amount of market value added to the funds.
Stocks to Buy Now: Two Intoxicating Recession-Proof Plays
As you look for stocks to buy now, it's as simple as watching the behavior around you...
For example, you might feel like the fiscal cliff, devastation from Superstorm Sandy and more gridlock in Washington is enough to drive you to drink.
And millions of people are doing just that.
Even in the worst of times, alcoholic beverage companies continue to generate rock-steady revenues and surging profits -- no matter what the rest of the market is doing.
Truth is, not many people will give up their nightly rituals, even if times are tough. During the Great Recession, booze purveyors have been particularly resilient, making them good stocks to buy ahead of slow growth in 2013.
Over the last five years, the S&P 500 has returned less than 1.2% annually. By contrast, a Wine, Beer, and Spirits Folio focused on the sector returned 9.1% per year.
Better yet, beer, wine and liquor makers are one of the few industries that have been able to raise prices, according to an industry report by Value Line.
To cash in on this trend, consider the stocks of these two stalwart beverage companies.
For example, you might feel like the fiscal cliff, devastation from Superstorm Sandy and more gridlock in Washington is enough to drive you to drink.
And millions of people are doing just that.
Even in the worst of times, alcoholic beverage companies continue to generate rock-steady revenues and surging profits -- no matter what the rest of the market is doing.
Truth is, not many people will give up their nightly rituals, even if times are tough. During the Great Recession, booze purveyors have been particularly resilient, making them good stocks to buy ahead of slow growth in 2013.
Over the last five years, the S&P 500 has returned less than 1.2% annually. By contrast, a Wine, Beer, and Spirits Folio focused on the sector returned 9.1% per year.
Better yet, beer, wine and liquor makers are one of the few industries that have been able to raise prices, according to an industry report by Value Line.
To cash in on this trend, consider the stocks of these two stalwart beverage companies.
To continue reading, please click here...
Three Biotech Stocks to Buy Now
If you're looking to hit a home run over the next 12 months, your best bet for stocks to buy now is biotechnology companies - especially those focused on cancer research.
Here's why: biotech stocks have been in a stealth bull market in 2012.
In fact, the values of the 230 publicly-traded biotech companies tracked by the BioWorld Stock Report have jumped by an average 38% year-to-date.
The third quarter was especially hot. The Nasdaq Biotechnology Index rose 10% over that time frame and is up a healthy 37% this year.
And, nothing is hotter than companies focused on the battle against cancer.
Take Medivation Inc. (Nasdaq: MDVN), for example. This California-based biotech has jumped from $23 to $46 a share, largely on the approval of Xtandi, its novel prostate cancer drug.
Thousands of other experimental drugs are going through various stages of clinical trials, and the largest category in the pipeline is cancer drugs. With that in mind, it's safe to say that if you're looking for a stock with big upside potential, cancer-driven biotech stocks should be high on your list. Biotech Stocks: Cancer Research is Paying Off
A cancer diagnosis was once a death sentence -- especially if you were diagnosed with the disease in its late stages.
But, both government and industry have spent vast sums in the last decade researching how cancers develop and spread.
And now all that investment is starting to pay off -- recent clinical trials and treatment breakthroughs show real promise.
The newest cancer research focuses on three fronts.
Here's why: biotech stocks have been in a stealth bull market in 2012.
In fact, the values of the 230 publicly-traded biotech companies tracked by the BioWorld Stock Report have jumped by an average 38% year-to-date.
The third quarter was especially hot. The Nasdaq Biotechnology Index rose 10% over that time frame and is up a healthy 37% this year.
And, nothing is hotter than companies focused on the battle against cancer.
Take Medivation Inc. (Nasdaq: MDVN), for example. This California-based biotech has jumped from $23 to $46 a share, largely on the approval of Xtandi, its novel prostate cancer drug.
Thousands of other experimental drugs are going through various stages of clinical trials, and the largest category in the pipeline is cancer drugs. With that in mind, it's safe to say that if you're looking for a stock with big upside potential, cancer-driven biotech stocks should be high on your list. Biotech Stocks: Cancer Research is Paying Off
A cancer diagnosis was once a death sentence -- especially if you were diagnosed with the disease in its late stages.
But, both government and industry have spent vast sums in the last decade researching how cancers develop and spread.
And now all that investment is starting to pay off -- recent clinical trials and treatment breakthroughs show real promise.
The newest cancer research focuses on three fronts.
To continue reading, please click here...